Albert David Limited has informed the Exchange about General Updates about KMP'S authorised to determine Materiality under Regulation 30(5) of SEBI(LODR),2015
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited's Board meeting on May 12, 2026 approved appointment of Mr. Amit Mahla as CEO (effective same day), filling a vacancy since Mr. Umesh Manohar Kunte resigned as Managing Director & CEO on December 18, 2025. FY2026 financials show significant decline: revenue Rs. 33,359.81 lakh vs Rs. 34,576.80 lakh prior year, with the company reporting a loss of Rs. 149.47 lakh (vs profit of Rs. 1,720.08 lakh in FY2025), and EPS of -Rs. 2.62 (vs Rs. 30.14). The Board recommended a 50% final dividend of Rs. 5 per share (face value Rs. 10), subject to shareholder approval at the August 6, 2026 AGM. Statutory auditors L.B. Jha & Co. issued an unmodified opinion. PricewaterhouseCoopers was reappointed as internal auditors and S. Gupta & Co. as cost auditors for FY2026-27. The company also updated authorized KMP contacts for SEBI disclosure purposes.
The appointment of a new external CEO with pharma industry experience may provide strategic direction amid challenging financials. However, the significant drop in FY2026 profitability (from ~Rs. 17 crore profit to loss) is concerning for shareholders. The dividend offer provides some return despite the loss-making year.